Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on autoimmune diseases, has appointed Dr. Adi Osovsky as General Counsel. Dr. Osovsky brings 17 years of experience in biotechnology and pharmaceutical legal counsel.
Dr. Osovsky joins from iTeos Therapeutics, where she served as Executive Vice President, Head of Legal & Corporate Secretary. She previously held senior legal roles at Sarepta Therapeutics and was an associate at Sullivan & Worcester LLP. She holds an LL.B. from Tel Aviv University and both an LL.M. and S.J.D. in Securities Regulation from Harvard Law School.
Vor Bio (Nasdaq: VOR), azienda biotecnologica in fase clinica specializzata nelle malattie autoimmuni, ha nominato la Dr.ssa Adi Osovsky General Counsel. La Dr.ssa Osovsky vanta 17 anni di esperienza come consulente legale nel settore biotec e farmaceutico.
La Dr.ssa Osovsky proviene da iTeos Therapeutics, dove ricopriva il ruolo di Executive Vice President, Head of Legal & Corporate Secretary. In precedenza ha occupato posizioni legali di vertice presso Sarepta Therapeutics ed è stata associata presso Sullivan & Worcester LLP. Ha conseguito un LL.B. presso l'Università di Tel Aviv e un LL.M. e un S.J.D. in Securities Regulation alla Harvard Law School.
Vor Bio (Nasdaq: VOR), una compañía biotecnológica en fase clínica centrada en enfermedades autoinmunes, ha nombrado a la Dra. Adi Osovsky como General Counsel. La Dra. Osovsky aporta 17 años de experiencia en asesoría legal en biotecnología y farmacéutica.
La Dra. Osovsky llega desde iTeos Therapeutics, donde ejercía como Executive Vice President, Head of Legal & Corporate Secretary. Anteriormente ocupó altos cargos legales en Sarepta Therapeutics y fue asociada en Sullivan & Worcester LLP. Posee un LL.B. por la Universidad de Tel Aviv y un LL.M. y un S.J.D. en Securities Regulation por la Harvard Law School.
Vor Bio (Nasdaq: VOR), 자가면역질환을 중점으로 하는 임상 단계의 바이오테크 기업이 아디 오소브스키 박사(Dr. Adi Osovsky)를 법률총괄(General Counsel)로 임명했습니다. 오소브스키 박사는 바이오·제약 분야에서 17년의 법률 자문 경력을 보유하고 있습니다.
오소브스키 박사는 iTeos Therapeutics에서 Executive Vice President, Head of Legal & Corporate Secretary로 재직하다 합류했습니다. 이전에는 Sarepta Therapeutics에서 고위 법무직을 역임했으며 Sullivan & Worcester LLP에서 변호사로 근무한 바 있습니다. 텔아비브 대학교에서 LL.B.를, 하버드 로스쿨에서 증권규제(Securities Regulation) 관련 LL.M. 및 S.J.D.를 취득했습니다.
Vor Bio (Nasdaq: VOR), une société biotechnologique en phase clinique spécialisée dans les maladies auto-immunes, a nommé Dr Adi Osovsky au poste de General Counsel. Le Dr Osovsky apporte 17 ans d'expérience en conseil juridique dans les secteurs de la biotechnologie et de la pharmacie.
Le Dr Osovsky rejoint Vor Bio en provenance d'iTeos Therapeutics, où elle était Executive Vice President, Head of Legal & Corporate Secretary. Elle a auparavant occupé des postes juridiques de haut niveau chez Sarepta Therapeutics et a été associée chez Sullivan & Worcester LLP. Elle est titulaire d'un LL.B. de l'Université de Tel Aviv ainsi que d'un LL.M. et d'un S.J.D. en Securities Regulation de la Harvard Law School.
Vor Bio (Nasdaq: VOR), ein biotechnologisches Unternehmen in klinischer Phase mit Schwerpunkt auf Autoimmunerkrankungen, hat Dr. Adi Osovsky zur General Counsel ernannt. Dr. Osovsky bringt 17 Jahre Erfahrung in der rechtlichen Beratung der Biotech- und Pharmabranche mit.
Dr. Osovsky kommt von iTeos Therapeutics, wo sie als Executive Vice President, Head of Legal & Corporate Secretary tätig war. Zuvor hatte sie leitende Rechtspositionen bei Sarepta Therapeutics inne und war Associate bei Sullivan & Worcester LLP. Sie besitzt einen LL.B. der Universität Tel Aviv sowie einen LL.M. und einen S.J.D. in Securities Regulation der Harvard Law School.
- Appointment of experienced legal counsel with 17 years of industry expertise
- New General Counsel brings specific experience in governance, compliance, and strategic transactions
- Addition strengthens leadership team as company advances late-stage clinical programs
- None.
Experienced legal leader brings deep expertise in governance, strategic transactions, and risk management to support Vor Bio’s growth
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors.
“We are delighted to welcome Adi to Vor Bio at this important stage in our growth,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. “Adi’s proven experience advising public biopharmaceutical companies on governance, compliance, and strategic transactions makes her an outstanding addition to our leadership team. Her counsel will be invaluable as we advance our late-stage clinical programs and prepare for growth.”
Dr. Osovsky joins Vor Bio from iTeos Therapeutics, where she served as Executive Vice President, Head of Legal & Corporate Secretary. In that role, she led all of the company’s corporate legal and compliance activities and oversaw information technology. She previously held senior legal roles at Sarepta Therapeutics, supporting corporate transactions, securities matters, and governance through a period of rapid growth and transformation. Earlier in her career, she was an associate in the Capital Markets practice at Sullivan & Worcester LLP, where she advised biotechnology and pharmaceutical companies on corporate finance, governance, and securities regulation.
Dr. Osovsky holds an LL.B. from Tel Aviv University and both an LL.M. and an S.J.D. in Securities Regulation from Harvard Law School.
“I am thrilled to join Vor Bio at such a pivotal time,” said Dr. Osovsky. “Vor Bio’s mission to transform the treatment of autoimmune diseases deeply resonates with me, and I look forward to partnering with this talented team to advance the company’s mission and enable long-term success for patients.”
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding its development and growth plans and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com
FAQ
Who is the new General Counsel at Vor Bio (Nasdaq: VOR)?
What is Dr. Adi Osovsky's previous experience before joining Vor Bio?
What are Vor Bio's current business priorities?
What is Vor Bio's main focus as a company?
What educational background does Dr. Osovsky bring to Vor Bio?
